img

Global Therapeutic Radioligands Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Therapeutic Radioligands Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Therapeutic Radioligands is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
Global Therapeutic Radioligands market is projected to reach US$ 4471.9 million in 2029, increasing from US$ 1043 million in 2022, with the CAGR of 17.4% during the period of 2024 to 2029. Demand from Solid Tumor and Non Hodgkin Lymphoma are the major drivers for the industry.
The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resource-intensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Therapeutic Radioligands market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Segment by Type
Beta-emitting
Targeted Alpha Therapy

Segment by Application


Solid Tumor
Non Hodgkin Lymphoma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Therapeutic Radioligands market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Therapeutic Radioligands introduction, etc. Therapeutic Radioligands Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Therapeutic Radioligands market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Therapeutic Radioligands
1.1 Therapeutic Radioligands Market Overview
1.1.1 Therapeutic Radioligands Product Scope
1.1.2 Therapeutic Radioligands Market Status and Outlook
1.2 Global Therapeutic Radioligands Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Therapeutic Radioligands Market Size by Region (2018-2029)
1.4 Global Therapeutic Radioligands Historic Market Size by Region (2018-2024)
1.5 Global Therapeutic Radioligands Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Therapeutic Radioligands Market Size (2018-2029)
1.6.1 North America Therapeutic Radioligands Market Size (2018-2029)
1.6.2 Europe Therapeutic Radioligands Market Size (2018-2029)
1.6.3 Asia-Pacific Therapeutic Radioligands Market Size (2018-2029)
1.6.4 Latin America Therapeutic Radioligands Market Size (2018-2029)
1.6.5 Middle East & Africa Therapeutic Radioligands Market Size (2018-2029)
2 Therapeutic Radioligands Market by Type
2.1 Introduction
2.1.1 Beta-emitting
2.1.2 Targeted Alpha Therapy
2.2 Global Therapeutic Radioligands Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Therapeutic Radioligands Historic Market Size by Type (2018-2024)
2.2.2 Global Therapeutic Radioligands Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Therapeutic Radioligands Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Therapeutic Radioligands Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Therapeutic Radioligands Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Therapeutic Radioligands Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Therapeutic Radioligands Revenue Breakdown by Type (2018-2029)
3 Therapeutic Radioligands Market Overview by Application
3.1 Introduction
3.1.1 Solid Tumor
3.1.2 Non Hodgkin Lymphoma
3.2 Global Therapeutic Radioligands Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Therapeutic Radioligands Historic Market Size by Application (2018-2024)
3.2.2 Global Therapeutic Radioligands Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Therapeutic Radioligands Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Therapeutic Radioligands Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Therapeutic Radioligands Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Therapeutic Radioligands Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Therapeutic Radioligands Revenue Breakdown by Application (2018-2029)
4 Therapeutic Radioligands Competition Analysis by Players
4.1 Global Therapeutic Radioligands Market Size by Players (2018-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Therapeutic Radioligands as of 2022)
4.3 Date of Key Players Enter into Therapeutic Radioligands Market
4.4 Global Top Players Therapeutic Radioligands Headquarters and Area Served
4.5 Key Players Therapeutic Radioligands Product Solution and Service
4.6 Competitive Status
4.6.1 Therapeutic Radioligands Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bayer
5.1.1 Bayer Profile
5.1.2 Bayer Main Business
5.1.3 Bayer Therapeutic Radioligands Products, Services and Solutions
5.1.4 Bayer Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.1.5 Bayer Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Therapeutic Radioligands Products, Services and Solutions
5.2.4 Novartis Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.2.5 Novartis Recent Developments
5.3 Lantheus
5.3.1 Lantheus Profile
5.3.2 Lantheus Main Business
5.3.3 Lantheus Therapeutic Radioligands Products, Services and Solutions
5.3.4 Lantheus Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.3.5 Aurobindo Pharma Recent Developments
5.4 Aurobindo Pharma
5.4.1 Aurobindo Pharma Profile
5.4.2 Aurobindo Pharma Main Business
5.4.3 Aurobindo Pharma Therapeutic Radioligands Products, Services and Solutions
5.4.4 Aurobindo Pharma Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.4.5 Aurobindo Pharma Recent Developments
5.5 Mundipharma
5.5.1 Mundipharma Profile
5.5.2 Mundipharma Main Business
5.5.3 Mundipharma Therapeutic Radioligands Products, Services and Solutions
5.5.4 Mundipharma Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.5.5 Mundipharma Recent Developments
5.6 China Isotope & Radiation
5.6.1 China Isotope & Radiation Profile
5.6.2 China Isotope & Radiation Main Business
5.6.3 China Isotope & Radiation Therapeutic Radioligands Products, Services and Solutions
5.6.4 China Isotope & Radiation Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.6.5 China Isotope & Radiation Recent Developments
5.7 Curium Pharmaceuticals
5.7.1 Curium Pharmaceuticals Profile
5.7.2 Curium Pharmaceuticals Main Business
5.7.3 Curium Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
5.7.4 Curium Pharmaceuticals Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.7.5 Curium Pharmaceuticals Recent Developments
5.8 Gilead Sciences
5.8.1 Gilead Sciences Profile
5.8.2 Gilead Sciences Main Business
5.8.3 Gilead Sciences Therapeutic Radioligands Products, Services and Solutions
5.8.4 Gilead Sciences Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.8.5 Gilead Sciences Recent Developments
5.9 Clarity Pharmaceuticals
5.9.1 Clarity Pharmaceuticals Profile
5.9.2 Clarity Pharmaceuticals Main Business
5.9.3 Clarity Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
5.9.4 Clarity Pharmaceuticals Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.9.5 Clarity Pharmaceuticals Recent Developments
5.10 Curasight
5.10.1 Curasight Profile
5.10.2 Curasight Main Business
5.10.3 Curasight Therapeutic Radioligands Products, Services and Solutions
5.10.4 Curasight Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.10.5 Curasight Recent Developments
5.11 Nordic Nanovector
5.11.1 Nordic Nanovector Profile
5.11.2 Nordic Nanovector Main Business
5.11.3 Nordic Nanovector Therapeutic Radioligands Products, Services and Solutions
5.11.4 Nordic Nanovector Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.11.5 Nordic Nanovector Recent Developments
5.12 Philogen
5.12.1 Philogen Profile
5.12.2 Philogen Main Business
5.12.3 Philogen Therapeutic Radioligands Products, Services and Solutions
5.12.4 Philogen Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.12.5 Philogen Recent Developments
5.13 RadioMedix
5.13.1 RadioMedix Profile
5.13.2 RadioMedix Main Business
5.13.3 RadioMedix Therapeutic Radioligands Products, Services and Solutions
5.13.4 RadioMedix Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.13.5 RadioMedix Recent Developments
5.14 Telix Pharmaceuticals
5.14.1 Telix Pharmaceuticals Profile
5.14.2 Telix Pharmaceuticals Main Business
5.14.3 Telix Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
5.14.4 Telix Pharmaceuticals Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.14.5 Telix Pharmaceuticals Recent Developments
5.15 Orano Med
5.15.1 Orano Med Profile
5.15.2 Orano Med Main Business
5.15.3 Orano Med Therapeutic Radioligands Products, Services and Solutions
5.15.4 Orano Med Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.15.5 Orano Med Recent Developments
5.16 Actinium Pharmaceuticals
5.16.1 Actinium Pharmaceuticals Profile
5.16.2 Actinium Pharmaceuticals Main Business
5.16.3 Actinium Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
5.16.4 Actinium Pharmaceuticals Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.16.5 Actinium Pharmaceuticals Recent Developments
5.17 Y-mAbs Therapeutics
5.17.1 Y-mAbs Therapeutics Profile
5.17.2 Y-mAbs Therapeutics Main Business
5.17.3 Y-mAbs Therapeutics Therapeutic Radioligands Products, Services and Solutions
5.17.4 Y-mAbs Therapeutics Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.17.5 Y-mAbs Therapeutics Recent Developments
5.18 Fusion Pharmaceuticals
5.18.1 Fusion Pharmaceuticals Profile
5.18.2 Fusion Pharmaceuticals Main Business
5.18.3 Fusion Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
5.18.4 Fusion Pharmaceuticals Therapeutic Radioligands Revenue (US$ Million) & (2018-2024)
5.18.5 Fusion Pharmaceuticals Recent Developments
6 North America
6.1 North America Therapeutic Radioligands Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Therapeutic Radioligands Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Therapeutic Radioligands Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Therapeutic Radioligands Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Therapeutic Radioligands Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Therapeutic Radioligands Market Dynamics
11.1 Therapeutic Radioligands Industry Trends
11.2 Therapeutic Radioligands Market Drivers
11.3 Therapeutic Radioligands Market Challenges
11.4 Therapeutic Radioligands Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Therapeutic Radioligands Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
Table 2. Global Therapeutic Radioligands Market Size by Region (2018-2024) & (US$ Million)
Table 3. Global Therapeutic Radioligands Market Size Share by Region (2018-2024)
Table 4. Global Therapeutic Radioligands Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 5. Global Therapeutic Radioligands Forecasted Market Size Share by Region (2024-2029)
Table 6. Global Therapeutic Radioligands Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
Table 7. Global Therapeutic Radioligands Market Size by Type (2018-2024) & (US$ Million)
Table 8. Global Therapeutic Radioligands Revenue Market Share by Type (2018-2024)
Table 9. Global Therapeutic Radioligands Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 10. Global Therapeutic Radioligands Revenue Market Share by Type (2024-2029)
Table 11. North America Therapeutic Radioligands Revenue by Type (2018-2024) & (US$ Million)
Table 12. North America Therapeutic Radioligands Revenue by Type (2024-2029) & (US$ Million)
Table 13. Europe Therapeutic Radioligands Revenue by Type (2018-2024) & (US$ Million)
Table 14. Europe Therapeutic Radioligands Revenue by Type (2024-2029) & (US$ Million)
Table 15. Asia-Pacific Therapeutic Radioligands Revenue by Type (2018-2024) & (US$ Million)
Table 16. Asia-Pacific Therapeutic Radioligands Revenue by Type (2024-2029) & (US$ Million)
Table 17. Latin America Therapeutic Radioligands Revenue by Type (2018-2024) & (US$ Million)
Table 18. Latin America Therapeutic Radioligands Revenue by Type (2024-2029) & (US$ Million)
Table 19. Middle East and Africa Therapeutic Radioligands Revenue by Type (2018-2024) & (US$ Million)
Table 20. Middle East and Africa Therapeutic Radioligands Revenue by Type (2024-2029) & (US$ Million)
Table 21. Global Therapeutic Radioligands Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
Table 22. Global Therapeutic Radioligands Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Therapeutic Radioligands Revenue Market Share by Application (2018-2024)
Table 24. Global Therapeutic Radioligands Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 25. Global Therapeutic Radioligands Revenue Market Share by Application (2024-2029)
Table 26. North America Therapeutic Radioligands Revenue by Application (2018-2024) & (US$ Million)
Table 27. North America Therapeutic Radioligands Revenue by Application (2024-2029) & (US$ Million)
Table 28. Europe Therapeutic Radioligands Revenue by Application (2018-2024) & (US$ Million)
Table 29. Europe Therapeutic Radioligands Revenue by Application (2024-2029) & (US$ Million)
Table 30. Asia-Pacific Therapeutic Radioligands Revenue by Application (2018-2024) & (US$ Million)
Table 31. Asia-Pacific Therapeutic Radioligands Revenue by Application (2024-2029) & (US$ Million)
Table 32. Latin America Therapeutic Radioligands Revenue by Application (2018-2024) & (US$ Million)
Table 33. Latin America Therapeutic Radioligands Revenue by Application (2024-2029) & (US$ Million)
Table 34. Middle East and Africa Therapeutic Radioligands Revenue by Application (2018-2024) & (US$ Million)
Table 35. Middle East and Africa Therapeutic Radioligands Revenue by Application (2024-2029) & (US$ Million)
Table 36. Global Therapeutic Radioligands Revenue (US$ Million) by Players (2018-2024)
Table 37. Global Therapeutic Radioligands Revenue Market Share by Players (2018-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Therapeutic Radioligands as of 2022)
Table 39. Date of Key Players Enter into Therapeutic Radioligands Market
Table 40. Global Therapeutic Radioligands Key Players Headquarters and Area Served
Table 41. Therapeutic Radioligands Product Solution and Service
Table 42. Global Therapeutic Radioligands Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Bayer Basic Information List
Table 45. Bayer Description and Business Overview
Table 46. Bayer Therapeutic Radioligands Products, Services and Solutions
Table 47. Revenue (US$ Million) in Therapeutic Radioligands Business of Bayer (2018-2024)
Table 48. Bayer Recent Developments
Table 49. Novartis Basic Information List
Table 50. Novartis Description and Business Overview
Table 51. Novartis Therapeutic Radioligands Products, Services and Solutions
Table 52. Revenue (US$ Million) in Therapeutic Radioligands Business of Novartis (2018-2024)
Table 53. Novartis Recent Developments
Table 54. Lantheus Basic Information List
Table 55. Lantheus Description and Business Overview
Table 56. Lantheus Therapeutic Radioligands Products, Services and Solutions
Table 57. Revenue (US$ Million) in Therapeutic Radioligands Business of Lantheus (2018-2024)
Table 58. Lantheus Recent Developments
Table 59. Aurobindo Pharma Basic Information List
Table 60. Aurobindo Pharma Description and Business Overview
Table 61. Aurobindo Pharma Therapeutic Radioligands Products, Services and Solutions
Table 62. Revenue (US$ Million) in Therapeutic Radioligands Business of Aurobindo Pharma (2018-2024)
Table 63. Aurobindo Pharma Recent Developments
Table 64. Mundipharma Basic Information List
Table 65. Mundipharma Description and Business Overview
Table 66. Mundipharma Therapeutic Radioligands Products, Services and Solutions
Table 67. Revenue (US$ Million) in Therapeutic Radioligands Business of Mundipharma (2018-2024)
Table 68. Mundipharma Recent Developments
Table 69. China Isotope & Radiation Basic Information List
Table 70. China Isotope & Radiation Description and Business Overview
Table 71. China Isotope & Radiation Therapeutic Radioligands Products, Services and Solutions
Table 72. Revenue (US$ Million) in Therapeutic Radioligands Business of China Isotope & Radiation (2018-2024)
Table 73. China Isotope & Radiation Recent Developments
Table 74. Curium Pharmaceuticals Basic Information List
Table 75. Curium Pharmaceuticals Description and Business Overview
Table 76. Curium Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
Table 77. Revenue (US$ Million) in Therapeutic Radioligands Business of Curium Pharmaceuticals (2018-2024)
Table 78. Curium Pharmaceuticals Recent Developments
Table 79. Gilead Sciences Basic Information List
Table 80. Gilead Sciences Description and Business Overview
Table 81. Gilead Sciences Therapeutic Radioligands Products, Services and Solutions
Table 82. Revenue (US$ Million) in Therapeutic Radioligands Business of Gilead Sciences (2018-2024)
Table 83. Gilead Sciences Recent Developments
Table 84. Clarity Pharmaceuticals Basic Information List
Table 85. Clarity Pharmaceuticals Description and Business Overview
Table 86. Clarity Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
Table 87. Revenue (US$ Million) in Therapeutic Radioligands Business of Clarity Pharmaceuticals (2018-2024)
Table 88. Clarity Pharmaceuticals Recent Developments
Table 89. Curasight Basic Information List
Table 90. Curasight Description and Business Overview
Table 91. Curasight Therapeutic Radioligands Products, Services and Solutions
Table 92. Revenue (US$ Million) in Therapeutic Radioligands Business of Curasight (2018-2024)
Table 93. Curasight Recent Developments
Table 94. Nordic Nanovector Basic Information List
Table 95. Nordic Nanovector Description and Business Overview
Table 96. Nordic Nanovector Therapeutic Radioligands Products, Services and Solutions
Table 97. Revenue (US$ Million) in Therapeutic Radioligands Business of Nordic Nanovector (2018-2024)
Table 98. Nordic Nanovector Recent Developments
Table 99. Philogen Basic Information List
Table 100. Philogen Description and Business Overview
Table 101. Philogen Therapeutic Radioligands Products, Services and Solutions
Table 102. Revenue (US$ Million) in Therapeutic Radioligands Business of Philogen (2018-2024)
Table 103. Philogen Recent Developments
Table 104. RadioMedix Basic Information List
Table 105. RadioMedix Description and Business Overview
Table 106. RadioMedix Therapeutic Radioligands Products, Services and Solutions
Table 107. Revenue (US$ Million) in Therapeutic Radioligands Business of RadioMedix (2018-2024)
Table 108. RadioMedix Recent Developments
Table 109. Telix Pharmaceuticals Basic Information List
Table 110. Telix Pharmaceuticals Description and Business Overview
Table 111. Telix Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
Table 112. Revenue (US$ Million) in Therapeutic Radioligands Business of Telix Pharmaceuticals (2018-2024)
Table 113. Telix Pharmaceuticals Recent Developments
Table 114. Orano Med Basic Information List
Table 115. Orano Med Description and Business Overview
Table 116. Orano Med Therapeutic Radioligands Products, Services and Solutions
Table 117. Revenue (US$ Million) in Therapeutic Radioligands Business of Orano Med (2018-2024)
Table 118. Orano Med Recent Developments
Table 119. Actinium Pharmaceuticals Basic Information List
Table 120. Actinium Pharmaceuticals Description and Business Overview
Table 121. Actinium Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
Table 122. Revenue (US$ Million) in Therapeutic Radioligands Business of Actinium Pharmaceuticals (2018-2024)
Table 123. Actinium Pharmaceuticals Recent Developments
Table 124. Y-mAbs Therapeutics Basic Information List
Table 125. Y-mAbs Therapeutics Description and Business Overview
Table 126. Y-mAbs Therapeutics Therapeutic Radioligands Products, Services and Solutions
Table 127. Revenue (US$ Million) in Therapeutic Radioligands Business of Y-mAbs Therapeutics (2018-2024)
Table 128. Y-mAbs Therapeutics Recent Developments
Table 129. Fusion Pharmaceuticals Basic Information List
Table 130. Fusion Pharmaceuticals Description and Business Overview
Table 131. Fusion Pharmaceuticals Therapeutic Radioligands Products, Services and Solutions
Table 132. Revenue (US$ Million) in Therapeutic Radioligands Business of Fusion Pharmaceuticals (2018-2024)
Table 133. Fusion Pharmaceuticals Recent Developments
Table 134. North America Therapeutic Radioligands Market Size by Country (2018-2024) & (US$ Million)
Table 135. North America Therapeutic Radioligands Market Size by Country (2024-2029) & (US$ Million)
Table 136. Europe Therapeutic Radioligands Market Size by Country (2018-2024) & (US$ Million)
Table 137. Europe Therapeutic Radioligands Market Size by Country (2024-2029) & (US$ Million)
Table 138. Asia-Pacific Therapeutic Radioligands Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 139. Asia-Pacific Therapeutic Radioligands Market Size by Region (2018-2024) & (US$ Million)
Table 140. Asia-Pacific Therapeutic Radioligands Market Size by Region (2024-2029) & (US$ Million)
Table 141. Asia-Pacific Therapeutic Radioligands Market Share by Region (2018-2024)
Table 142. Asia-Pacific Therapeutic Radioligands Market Share by Region (2024-2029)
Table 143. Latin America Therapeutic Radioligands Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 144. Latin America Therapeutic Radioligands Market Size by Country (2018-2024) & (US$ Million)
Table 145. Latin America Therapeutic Radioligands Market Size by Country (2024-2029) & (US$ Million)
Table 146. Middle East & Africa Therapeutic Radioligands Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 147. Middle East & Africa Therapeutic Radioligands Market Size by Country (2018-2024) & (US$ Million)
Table 148. Middle East & Africa Therapeutic Radioligands Market Size by Country (2024-2029) & (US$ Million)
Table 149. Therapeutic Radioligands Market Trends
Table 150. Therapeutic Radioligands Market Drivers
Table 151. Therapeutic Radioligands Market Challenges
Table 152. Therapeutic Radioligands Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Therapeutic Radioligands Market Size Year-over-Year 2018-2029 & (US$ Million)
Figure 2. Global Therapeutic Radioligands Market Size (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Therapeutic Radioligands Market Share by Regions: 2022 VS 2029
Figure 4. Global Therapeutic Radioligands Forecasted Market Size Share by Region (2024-2029)
Figure 5. North America Therapeutic Radioligands Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 6. Europe Therapeutic Radioligands Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 7. Asia-Pacific Therapeutic Radioligands Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 8. Latin America Therapeutic Radioligands Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 9. Middle East & Africa Therapeutic Radioligands Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 10. Product Picture of Beta-emitting
Figure 11. Global Beta-emitting Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 12. Product Picture of Targeted Alpha Therapy
Figure 13. Global Targeted Alpha Therapy Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 14. Global Therapeutic Radioligands Market Size Share by Type: 2022 & 2029
Figure 15. North America Therapeutic Radioligands Revenue Market Share by Type (2018-2029)
Figure 16. Europe Therapeutic Radioligands Revenue Market Share by Type (2018-2029)
Figure 17. Asia-Pacific Therapeutic Radioligands Revenue Market Share by Type (2018-2029)
Figure 18. Latin America Therapeutic Radioligands Revenue Market Share by Type (2018-2029)
Figure 19. Middle East and Africa Therapeutic Radioligands Revenue Market Share by Type (2018-2029)
Figure 20. Solid Tumor Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 21. Non Hodgkin Lymphoma Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 22. Global Therapeutic Radioligands Market Size Share by Application: 2022 & 2029
Figure 23. North America Therapeutic Radioligands Revenue Market Share by Application (2018-2029)
Figure 24. Europe Therapeutic Radioligands Revenue Market Share by Application (2018-2029)
Figure 25. Asia-Pacific Therapeutic Radioligands Revenue Market Share by Application (2018-2029)
Figure 26. Latin America Therapeutic Radioligands Revenue Market Share by Application (2018-2029)
Figure 27. Middle East and Africa Therapeutic Radioligands Revenue Market Share by Application (2018-2029)
Figure 28. Therapeutic Radioligands Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 29. Global Top 5 and Top 10 Players Therapeutic Radioligands Market Share in 2022
Figure 30. North America Therapeutic Radioligands Market Share by Country (2018-2029)
Figure 31. United States Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 32. Canada Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 33. Germany Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 34. France Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 35. U.K. Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 36. Italy Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 37. Russia Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 38. Nordic Countries Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 39. Asia-Pacific Therapeutic Radioligands Market Share by Region (2018-2029)
Figure 40. China Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 41. Japan Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 42. South Korea Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 43. Southeast Asia Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 44. India Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 45. Australia Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 46. Latin America Therapeutic Radioligands Market Share by Country (2018-2029)
Figure 47. Mexico Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 48. Brazil Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Therapeutic Radioligands Market Share by Country (2018-2029)
Figure 50. Turkey Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 52. UAE Therapeutic Radioligands Market Size (2018-2029) & (US$ Million)
Figure 53. Bottom-up and Top-down Approaches for This Report